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Abstract: Quinoline-based scaffolds have been the mainstay of antimalarial drugs, including many
artemisinin combination therapies (ACTs), over the history of modern drug development. Although much
progress has been made in the search for novel antimalarial scaffolds, it may be that quinolines will remain
useful, especially if very potent compounds from this class are discovered. We report here the results of a
structure-activity relationship (SAR) study assessing potential unsymmetrical bisquinoline antiplasmodial
drug candidates using in vitro activity against intact parasites in cell culture. Many unsymmetrical
bisquinolines were found to be highly potent against both chloroquine-sensitive and chloroquine-resistant
Plasmodium falciparum parasites. Further work to develop such compounds could focus on minimizing
toxicities in order to find suitable candidates for clinical evaluation.
Keywords: malaria; P. falciparum; drug discovery; SAR; structure–activity relationship; drug resistance
1. Introduction
Malaria remains a challenge for worldwide public health. The World Health Organization estimated
the total number of deaths in 2018 to be 405,000, down from 585,000 in 2010 and 864,000 in 2000 [1,2].
While there has been considerable progress and optimism about malaria elimination, eradication
may not be rapid. So as not to squander the progress that has been made, every possible new tool is
needed, especially in light of the development of drug resistance to nearly every current therapeutic
for P. falciparum malaria [3–5].
Bisquinolines have been explored for malaria for a long time, and the most successful of these,
piperaquine (PPQ; Table 1), has been used as both mono- and combination therapy [6]. Piperaquine
is a long-acting component of dihydroartemisinin-piperaquine, one of the artemisinin combination
therapies recommended by the World Health Organization to treat P. falciparum malaria [7]. PPQ and
a variety of analogs were first synthesized in France at Rhône-Poulenc [8–11] (Table 1) and further
developed in China. Clinical trials performed in China during the early 1970s led to piperaquine’s
wide use in China, both as treatment and as prophylaxis for P. falciparum and P. vivax malaria [12–16].
Piperaquine is believed to work by a mechanism similar to that of chloroquine and other 4-
aminoquinolines [15]; however, it retains activity against many chloroquine-resistant (CQR) strains,
perhaps because its large size prevents it being exported by the chloroquine resistance transporter [15,17–20].
However, following its introduction in China, resistance to PPQ monotherapy became common in the areas
in which it was heavily used [12–14]. Unfortunately, resistance to the combination dihydroartemisinin–
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piperaquine has now arisen and continues to increase in southeast Asia [21–23]. Recent work is uncovering
the mechanisms of piperaquine resistance [5,24–29].
In addition to PPQ itself, a wide range of other bis-4-aminoquinoline compounds have been shown
to have antiplasmodial activity, tending to be active against both chloroquine-sensitive (CQS) and CQR
strains [17,19,30–40]. During the 1990s, a study of bis-quinolines by Vennerstrom and co-workers led
to the discovery of Ro 48–6910, which was evaluated in preclinical studies but was regrettably found to
be phototoxic [19,37,41–44]. More recently, Kondaparla et al. have explored a series of unsymmetrical
bisquinolines linked by an amide and an adjacent chiral center [17].
Here, we report on a series of simple but unsymmetrical bisquinolines based on the 4-aminoquinoline
structure derived from CQ and other antimalarial drugs. One of these has unusually potent in vitro
activity against CQS and CQR malaria, indicating that structures in this series may be worth further
evaluation as antimalarials.
2. Results
In vitro antiplasmodial activities againstP. falciparum are given in Table 1. The bisquinoline compounds
vary in their alkylamine linkage between quinoline ring systems (alkyl, piperazine, or piperidine moieties).
Compound 1 is similar to PPQ, except that it lacks the quinoline Cl atoms. Like piperaquine, the bisquinoline
5 was originally reported by Rhône-Poulenc during the 1960s [45]; it is here compared with a des-chloro
analog, 7. Finally, we report a series of compounds based on the unsymmetrical bisquinoline compound
6 that vary in their quinoline ring substitution pattern (7-chloro, 8-trifluoromethyl, or no substituent).
For comparison to the bisquinolines, we also include compounds 2 and 4 from earlier work in our laboratory,
together with 3, the des-chloro analog of compound 2.
As can be seen from these results, bisquinoline structures can give very potent antimalarial
activities against the standard laboratory-adapted D6, Dd2, and 7G8 strains, the last two being accepted
CQR strains. However, cytotoxicity of an unsymmetrical bisquinoline assessed in mouse spleen
lymphocytes was found to be elevated relative to that of chloroquine.
Table 1. In vitro antiplasmodial activities of bisquinoline and related compounds.
Compound
Activity (IC50; nM) Cytotoxicity
Structure
D6 Dd2 7G8 (LC50; nM) MouseSpleen Lymphocytes
CQ 6.9 102 106 12,400
Molecules 2020, 25, x FOR PEER REVIEW 2 of 15 
 
common in the areas in which it was heavily used [12–14]. Unfortunately, resistance to the 
combination dihydroartemisinin–piperaquine has now arisen and continues to increase in southeast 
Asia [21–23]. Recent work is uncoveri g the mechanisms of piperaquine resistanc  [5,24–29]. 
In addition t  PPQ itself, a wide range of other bis-4-aminoquinoline compounds have been 
shown to have an iplasmodial ctivity, tending to be active against both chloroquine-sensitive (CQS) 
and CQR s rain  [17,19,30–40]. During the 1990s, a study of is-quin lines by Vennerstrom and co-
workers led to the discovery of Ro 48–6910, which was evaluated in preclinical stu ies but was 
regrettably found to be phototoxic [19,37,41–44]. More recently, Kondaparla et al. have explored a 
series of unsymmetrical bisquinolines linked by an amide and an adjacent chiral center [17]. 
Here, we report on a series of simple but unsymmetrical bisquinolines based on the 4-
aminoquinoline structure derived from CQ and other antimalarial drugs. One of these has unusually 
potent in vitro activity against CQS and CQR malaria, indicating that structures in this series may be 
worth further evaluation as antimalarials. 
2. Results 
In vitro antiplasmodial activities against P. falciparum are given in Table 1. The bisquinoline 
compounds vary in their alkylamine linkage between quinoline ring systems (alkyl, piperazine, or 
piperidine moieties). Compound 1 is similar to PPQ, except that it lacks the quinoline Cl atoms. Like 
piperaquine, the bisquinoline 5 was originally reported by Rhône-Poulenc during the 1960s [45]; it is 
here compared with a des-chloro analog, 7. Finally, we report a series of compounds based on the 
unsymmetrical bisquinoline compound 6 that vary in their quinoline ring substitution pattern (7-
chloro, 8-trifluoromethyl, or no substituent). For comparison to the bisquinolines, we also include 
compounds 2 and 4 from earlier work in our laboratory, together with 3, the des-chloro analog of 
compound 2. 
As can be seen from these results, bisquinoline structures can give very potent antimalarial 
activities against the standard laboratory-adapted D6, Dd2, and 7G8 strains, the last two being 
accepted CQR strains. However, cytotoxicity of an unsymmetrical bisquinoline assessed in mouse 
spleen lymphocytes was found to be elevated relative to that of chloroquine. 
Table 1. In vitro antiplasmodial activities of bisquinoline and related compounds. 
Compound 
Activity (IC50; nM) Cytotoxicity 
Structure 
D6 Dd2 7G8 
(LC50; nM) 
Mouse Sple n 
Lymphocytes 
CQ 6.9 102 106 12,400 
 
PPQ 0.7 1.5   
 
1 1.3 4.1 7.4  
 
2 [46] 2.4 3.7 1.5 1100 
 
3 1.5 5.0  1600 
 
4 (DM1157) 
[46,47] 0.2 2.2 1.8 6500 
 
PPQ 0.7 1.5
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piperaquine, the bisquinoline 5 was originally reported by Rhône-Poulenc during the 1960s [45]; it is 
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Table 1. Cont.
Compound
Activity (IC50; nM) Cytotoxicity
Structure
D6 Dd2 7G8 (LC50; nM) MouseSpleen Lymphocytes
4 (DM1157) [46,47] 0.2 2.2 1.8 6500
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5 [45] 0.4 0.7 0.1  
 
6 0.15 0.36 0.33 190 
 
7 4.9 9.8 25  
 
8 0.68 2.1 0.63  
 
9 0.68 2.1 0.41  
 
10 15 89 106  
 
11 3.0 < 2.5 < 2.5  
 
12 4.5 < 2.5 < 2.5  
 
13 33 56 100  
 
3. Discussion 
The in vitro antiplasmodial activities obtained for the bisquinolines reported here are given in 
Table 1, together with chloroquine, piperaquine, and three compounds from earlier work in our 
laboratory that contain a chloroquine moiety with an attached reversal agent (“reversed 
chloroquines”) [46,48]. Some of the compounds, particularly compound 6, were found to be very 
active in vitro. Potency of these bisquinolines may be enhanced by the potential of both of the 
quinoline moieties in these molecules to interact with heme (a commonly invoked mechanism of 
action of the 4-aminoquinolines), an advantage that would also be available to piperaquine. 
However, a difference between compound 6 and piperaquine is that the 4-aminoquinoline nitrogens 
of compound 6 are secondary, while those of PPQ are tertiary; much of the earlier work on 4-
aminoquinolines and 9-aminoacridines has focused on secondary 4-amino derivatives [49–53]. 
During the 1930s and 1940s, prior to research indicating that the site of action of 4-aminoquinolines 
and 9-aminoacridines is the parasite’s acidic digestive vacuole, Schönhofer and coworkers observed 
that alkylation of the 9-amino group of quinacrine (Atebrine) diminished antimalarial activity. To 
explain this, they proposed that antimalarial activity of quinacrine-like compounds required an 
ability to tautomerize, with the 9-NH shifting to the ring N (this is not possible for the tertiary 9-
amino derivatives [49]). The in vitro antiplasmodial activity of chloroquine [15,50,54] as well as 
reversed chloroquine compounds (unpublished work from our laboratory) is also reduced, but not 
eliminated, by the presence of a tertiary 4-amino group. Egan has shown that aminoquinolines 
capable of stabilizing a positive charge on the quinoline ring nitrogen (2- and 4-aminoquinolines) 
have strong heme binding and are more basic, potentially leading to increased accumulation at the 
site of action in the parasite’s digestive vacuole (Figure 1 [55]). 
6 0.15 0.36 0.33 190
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ability to tautomerize, with the 9-NH shifting to the ring N (this is not possible for the tertiary 9-
amino derivatives [49]). The in vitro antiplasmodial activity of chloroquine [15,50,54] as well as 
reversed chloroquine compounds (unpublished work from our laboratory) is also reduced, but not 
eliminated, by the presence of a tertiary 4-amino group. Egan has shown that aminoquinolines 
capable of stabilizing a positive charge on the quinoline ring nitrogen (2- and 4-aminoquinolines) 
have strong heme binding and are more basic, potentially leading to increased accumulation at the 
site of action in the parasite’s digestive vacuole (Figure 1 [55]). 
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reversed chloroquine compounds (unpublished work from our laboratory) is also reduced, but not 
eliminated, by the presence of a tertiary 4-amino group. Egan has shown that aminoquinolines 
capable of stabilizing a positive charge on the quinoline ring nitrogen (2- and 4-aminoquinolines) 
have strong heme binding and are more basic, potentially leading to increased accumulation at the 
site of action in the parasite’s digestive vacuole (Figure 1 [55]). 
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3. Discussion
The in vitro a iplasm dial activities obtained for the bisquinolines eported here are given in
Table 1, together with chl roquine, piperaqui e, and three comp unds from earlier w rk in ur labo atory
that co ta n a chloroquine moiety with an attached r ve s l agent (“reversed ch oroquines”) [46,48].
Some of the compounds, particularly compound 6, er found to be very active i vitr . P te cy of these
bisqui olines m y be enhanced by the potenti l of both of the quinoline moieties in these molecules to
interact with h me (a commo ly inv ked mechanism of action of the 4-aminoquinolines), an advantage
that would also b available to piperaq ine. H wever, diff ence be ween compo nd 6 and piperaquine
is that the 4-aminoquinoline nitrogens of compoun 6 ar secondary, wh le those of PPQ are tertiary;
uch of the earlier work on 4-aminoquinolines and 9-aminoacridin s has focuse on sec ndary 4-amino
de iv tiv s [49–53]. During the 1930 nd 1940s, prior t research indic ting that the site of action
of 4-aminoquinolin s and 9- minoacridines s th par site’s acidic dig stive vacu le, Schönhof r and
coworkers observed that alkylation of the 9-amino group f i ri (At bri e) diminish d antim larial
activity. To explain this, they proposed that antimalarial activity of quinacrine-like compounds equired
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an ability to tautomerize, with the 9-NH shifting to the ring N (this is not possible for the tertiary 9-amino
derivatives [49]). The in vitro antiplasmodial activity of chloroquine [15,50,54] as well as reversed
chloroquine compounds (unpublished work from our laboratory) is also reduced, but not eliminated,
by the presence of a tertiary 4-amino group. Egan has shown that aminoquinolines capable of stabilizing
a positive charge on the quinoline ring nitrogen (2- and 4-aminoquinolines) have strong heme binding
and are more basic, potentially leading to increased accumulation at the site of action in the parasite’s
digestive vacuole (Figure 1 [55]).Molecules 2020, 25, x FOR PEER REVIEW 4 of 15 
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with two tertiary 4-aminoquinolines–is a highly active antimalarial. Warhurst proposed that while 
piperaquine’s accumulation in the aqueous acidic vacuole should be somewhat less than that of 
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(based on the empirically determined pKas and cLogP of both compounds; [15]). This may be 
significant in view of the evidence that hemozoin may form at the surface of or inside of lipid droplets 
within the digestive vacuole [15,56–58]. 
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give high activity [59]. This may also apply to compound 6, which is structurally similar to the 
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two orders of magnitude of potency relative to compound 6. However, for analogues of 6 with a 
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antimalarial action of compound 6. 
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the 7-chloro substituent [55,66–73], but we have observed that this may not be the case for reversed 
chloroquine compounds (see compounds 2 and 3, Table 1; [48]). Here, we report that PPQ’s in vitro 
activity is minimally affected by removal of chlorine. For two other bisquinoline scaffolds, 5 [45] and 
6, we found that activity of des-chloro analogs was reduced compared to the 7-chloro parent 
(compare 6 to 11, 12, and 13 and 5 to 7), although not as much as has been observed for chloroquine 
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out of the plane of the ring, r ducing resonance stabilization of the alternative form. [15]. This would
then result in reduced basicity of the ring nitrogen for such tertiary compounds, leading to reduce
accumulation in the ige tive vacuole. Expe im tal determination f the pKas of piperaquine has
shown that it is indeed less basic than CQ [15]. In spite of these bservations, the bis i oline
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to be of equal importance to the antiplasm dial activity. This conclusion is apparent from the various
analogs with 8-trifluoromethyl substitution, which has been observed t be an inactivating substitution
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work in our lab) and for other 4-aminoquinol s, including bis i li s, although not for quinoline
methanols, such as mefloquine [60–64] (and in one study, not for 4-am obisquinolines where a 2-
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t both quinoline rings without the 7-Cl, l ses at east two orders of m gnitude of potency relative to
6. However, for analogues of 6 with a single 8-trifluoromethyl subs itution (c mpounds 8
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and 9), activity was almost as high as the parent 6. These results suggest that either quinoline ring system
is equally capable of participating in the antimalarial action of compound 6.
Others have noted that the activity of CQ and its analogs is detrimentally affected by removal of
the 7-chloro substituent [55,66–73], but we have observed that this may not be the case for reversed
chloroquine compounds (see compounds 2 and 3, Table 1; [48]). Here, we report that PPQ’s in vitro
activity is minimally affected by removal of chlorine. For two other bisquinoline scaffolds, 5 [45]
and 6, we found that activity of des-chloro analogs was reduced compared to the 7-chloro parent
(compare 6 to 11, 12, and 13 and 5 to 7), although not as much as has been observed for chloroquine
and analogs. Both 5 and 6 differ from piperaquine in having a secondary rather than tertiary 4-amino
group. This result suggests that secondary amino bisquinolines are more sensitive to removal of
chlorine than piperaquine. Even when just one ring system of 6 lacks a 7-chloro substituent, activity is
slightly diminished relative to the parent 6. For the 8-CF3 series, it appears that even with one ring
system “inactivated”, antimalarial activity does not decrease significantly. This does not appear to be
the case for des-chloro substitution.
4. Materials and Methods
Reagents and solvents were purchased from TCI America, Aldrich Chemical, Alfa Aesar, or Acros
Organics and were used as received without further purification.
4.1. General Synthetic Methods
Except for 4,7-dichloroquinoline, substituted 4-chloroquinolines were made by the Gould–Jacobs
reaction, followed by chlorination with phosphorus oxychloride (Figure 2 [74–77]):
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Bisquinoline products were purified by recrystallization and sometimes column chromatography.
A different, less satisfactory synthetic method was initially used to obtain compound 6. This is detailed
in the Supplementary Materials.
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4.2. Characterization of Products
Bisquinoline final products were characterized by NMR (1H, 13C, COSY, HSQC, NOESY, and 19F
if applicable), HPLC, and HR-MS (details of methods used below). Intermediates were characterized
by 1H NMR and in some cases HPLC and HR-MS.
1H, 13C, COSY, HSQC, HMBC, and 19F NMR experiments were run on a Bruker 400 MHz or
600 MHz spectrometer. (Note: Trifluoromethyl carbons were not observed in 13C NMR spectra, likely
due to reduction in intensity due to 19F–13C splitting as well as the lack of the 1-bond 1H–13C nuclear
Overhauser effect (NOE).) HPLC was performed using UV detection at 254 and 325 nm using a Varian
ProStar 325 UV/vis dual wavelength detector. Three HPLC methods were used. For HPLC method A,
a SUPELCO Ascentis RP-Amide 5 µm, 4.6 mm × 150 mm column was used, eluting with a gradient
of 95:5 to 30:70 water with 0.1% formic acid (v/v)/acetonitrile. For HPLC method B, a SUPELCO
Ascentis C18 5 µm, 4.6 × 150 mm column was used, eluting with 95% water and 5% acetonitrile.
For HPLC method C, a SUPELCO Ascentis C18 5 µm, 4.6 × 150 mm column was used, eluting with
a gradient from 95:5 to 5:95 water with 0.1% formic acid (v/v)/acetonitrile. High resolution mass
spectrometry was performed on a Bruker micrOTOF-Q instrument. Results were obtained using
electrospray ionization (ESI) in the positive mode at a flow rate of 0.4 mL/min with 1:1 methanol–water.
Gas chromatography–mass spectrometry (GC–MS) was performed using a Hewlett Packard HP5890
Series II gas chromatograph with a 30-m DB5 column. The oven temperature was set at 130 ◦C for
2 min and then increased to 300 ◦C at the rate of 30 ◦C per minute. This instrument was used with the
kind permission of Dr. Michael Riscoe of the Portland Veterans Affairs Medical Center.
Example Synthesis: Compound 6
(Further synthetic methods are provided in the Supplementary Materials).
3-(7-Dichloroquinolin-4-ylamino)propanol (Figure 8 [59,82]):
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Figure 8. Structure of 3-(7-Dichloroquinolin-4-ylamino)propanol.
The title compound was synthesized without deviating from methods previously described [59,82]
(a pale tan solid, mp = 148.5–151.0 ◦C).
3-(7-Chloroquinolin-4-yla ino)propyl ethanesulfonate (Figure 9 [59,82]):
o
C
Figure 9. Structure of 3-(7-Chloroquinolin-4-ylamino)propyl methanesulfonate.
3-(7-Dichloroquinolin-4-ylamino)propanol (1.88 g, 7.9 mmol), triethylamine (1.66 mL, 1.2 mmol),
and anhydrous THF (100 mL) were cooled below 0 ◦C on ice/salt, and methanesulfonyl chloride
(0.71 mL, 9.1 mmol) was added dropwise. After stirring for an hour on ice, TLC indicated that reaction
was not complete, and therefore additional triethylamine (0.83 mL, 6.0 mmol) and methanesulfonyl
chloride (0.36 mL, 6.0 mmol) were added. After a further hour, TLC indicated that no quinoline starting
material remained. The reaction mixture was diluted with ethyl acetate (30 mL) and shaken with
saturated sodium bicarbonate (30 mL), followed by extraction of the aqueous layer with additional
ethyl acetate (3 × 10 mL). The pooled ethyl acetate layers were washed with brine (10 mL), dried over
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magnesium sulfate, and evaporated under reduced pressure with warming to obtain a pale yellow,
fluffy solid (1.86 g, 81%).
1H NMR δ (ppm)(CDCl3): 8.53 (1 H, d, J = 5.37 Hz, ClQ-C2-H), 7.95 (1 H, d, J = 2.18 Hz, ClQ-C8-H),
7.72 (1 H, d, J = 8.97 Hz, ClQ-C5-H), 7.38 (1 H, dd, J = 8.94, 2.18 Hz, ClQ-C6-H), 6.42 (1 H, d, J = 5.40 Hz,
ClQ-C3-H), 5.55 (1 H, br t, J = 5.75 Hz, NH), 4.42 (2 H, t, J = 5.66 Hz, CH2O), 3.58 (2 H, td, J = 6.34,
5.77 Hz, CH2N), 3.06 (3 H, s, CH3), 2.18 (2 H, m, CH2).
Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate (Figure 10 [51,80])Molecules 2020, 25, x FOR PEER REVIEW 8 of 15 
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Figure 10. Structure of Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate.
4,7-Dichloroquinoline (2.00 g, 10 mmol), ethyl 4-amino-1-piperidine carboxylate (1.83 g, 11 mmol),
and phenol (5.70 g, 61 mol) were heated at 90 ◦C in a sealed Carius vessel for 48 h. TLC indicated
that unreacted 4,7-dichloroquinoline remained, and therefore additional ethyl 4-amino-1-piperidine
carboxylate (0.39 g, 2.3 mmol) was added. The vessel was again sealed and heated for a further 7 days,
whereupon TLC indicated that no unreacted quinoline remained. The reaction mixture was diluted
with chloroform (50 mL) and rinsed with 10% caustic soda (6 × 10 mL), followed by further rinsing
with brine (3 × 10 mL). The organic layer was dried over MgSO4 and concentrated under reduced
pressure with warming to yield a thick, tan liquid containing some solid material. After standing 14 h,
this was taken up in boiling solvent (50/50 ethyl acetate/95% ethanol (v/v)) and allowed to cool and
concentrate at room temperature. The crystals thus formed were recovered from the remaining 5 mL
of solvent by vacuum filtration (off-white crystals, 1.18 g, 35%, mp = 197.3–198.8 ◦C).
H NMR δ (ppm)(CDCl3): 8.54 (1 H, d, J = 5.36 Hz), 7.96 (1 H, d, J = 2.17 Hz), 7.66 (1 H, d, J = 8.98 Hz),
7.37 (1 H, dd, J = 8.94, 2.19 Hz), 6.46 (1 H, d, J = 5.41 Hz), 4.92 (1 H, br d, J = 7.25 Hz), 4.16 (4 H, br s
overlaps q, J = 7.13 Hz), 3.68–3.69 (1 H, m), 3.04 (2 H, td, J = 12.56, 2.82 Hz), 2.11–2.20 (2 H, m), 1.51–1.53
(2 H, m), 1.28 (3 H, t, J = 7.11 Hz).
MS (ESI): m/z 334.13271 M + H (calculated 334.13168).
HPLC (method A) tR = 10.55 min (99% pure).
7-Chloro-N-(piperidin-4-yl)quinolin-4-amine (Figure 11 [81])
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Figure 11. Structure of 7-Chloro-N-(piperidin-4-yl)quinolin-4-amine.
Ethyl 4-((7-chloroquinolin-4-yl)amino)piperidine-1-carboxylate (2.45 g, 7.3 mmol), 95% ethanol
(100 mL), and 10% caustic soda (4.5 mL) were allowed to heat, stirring, at reflux for 4 days. As TLC
indicated that the reaction was not complete, 0.5 mL of 50% caustic soda was added, and reflux was
continued for a further 3 days. TLC then indicated that the reaction was complete. The reaction
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solvent was removed under reduced pressure with warming, and the residue was partitioned between
chloroform (20 mL) and water (50 mL). After separation, the aqueous layer was extracted with
additional chloroform (3 × 10 mL), and the pooled organic layers were dried (MgSO4) and concentrated
under reduced pressure with warming to yield a tan solid (1.05 g). A cream-colored solid was also
isolated from the aqueous layer by vacuum filtration (1.04 g). NMR indicated that both solids obtained
were the desired product (total yield 1.83 g, 96%, mp = 166.3–169.4 ◦C).
1H NMR δ (ppm)(CDCl3): 8.52 (1 H, d, J = 5.39 Hz), 7.96 (1 H, d, J = 2.18 Hz), 7.65 (1 H, d, J = 8.96 Hz),
7.37 (1 H, dd, J = 8.93, 2.19 Hz), 6.45 (1 H, d, J = 5.42 Hz), 4.87 (1 H, br d, J = 7.35 Hz), 3.61–3.62 (1 H,
m), 3.19 (2 H, dt, J = 12.68, 3.70 Hz), 2.79–2.81 (2 H, m), 2.15–2.19 (2 H, m), 1.50–1.50 (2 H, m).
MS (ESI): m/z 262.11116 M + H (calculated 262.11065).
HPLC (method A) tR = 2.74 min (94% pure).
Compound 6 (7-Chloro-N-(3-(4-((7-chloroquinolin-4-yl)amino)piperidin-1-yl)propyl)quinolin-4-amine)
(Figure 12 [46,82])
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3-(7-Chloroquinolin-4-ylamino)propyl methanesulfonate (1.20 g, 3.8 mmol), 7-chloro-N-(piperidin-
4-yl)quinolin-4-amine (1.05 g, 4.0 mmol), potassiu carbonate (5.7 mmol, 0.79 g), a catalytic amount of
potassium iodide, and 50 mL anhy rous acetonitrile were allowed to heat for 48 h at r flux, whereupon
TLC indicated that the reaction was complete. The reaction mixture was diluted with water (50 mL) nd
vacuum filtered. The filtrate was concentrated under reduced pressure with warming, a the rea tion
mixture was partitioned betwee 50/50 dichloromethane/chloroform (20 mL) and 10 mL saturated
sodium bicarbo ate, followed by further extraction wi h three 10 mL portions f dichloromet ane.
The pooled organic layers were dried over anhydrous magnesium sulf te and conc ntrate under
reduced pressure. The resulting solid was combined with the material filtered from the reaction
mixture and recrystallized from 95% ethanol, which afforded the desired pro uct as a pale yellow,
crystalline solid (1.30 g). Concentration of the mother liquor yielded a further crop of crystals (0.06 g,
total yield 71%, mp = 224–227 ◦C (dec)).
1H NMR δ (ppm)(CDCl3): 8.56 (1 H, d, J = 5.33 Hz, Q1-C2-H), 8.53 (1 H, d, J = 5.33 Hz, Q2-C2-H), 7.99
(1 H, d, J = 2.16 Hz, Q1-C5-H), 7.97 (1 H, d, J = 2.14 Hz, Q2-C5-H), 7.78 (1 H, d, J = 8.90 Hz, Q2-C8-H),
7.71 (1 H, d, J = 8.95 Hz, Q1-C8-H), 7.43 (1 H, dd, J = 8.89, 2.18 Hz, Q1-C6-H), 7.35 (1 H, dd, J = 8.87,
2.16 Hz, Q2-C6-H), 7.02 (1 , br t, J = 4.27 Hz, Q1-C4-NH), 6.47 (1 H, d, J = 5.37 Hz, Q1-C3-H), 6.38 (1 H,
d, J = 5.37 Hz, Q2-C3- ), 4.92 (1 H, br d, J = 6.78 Hz, Q2-NH), 3.65 (1 H, m, Pip-CH), 3.42 (2 H, td, JCH2
= 6.01, JNH = 4.35 Hz, Q1-NHCH2CH2CH2), 3.06 ( H, m, piperidine-CH × 2 adjacent to alkyl chain),
2.67 (2 H, t, JCH2 = 5.64 Hz, Q1-NHCH CH2CH2), 2.33 (2 , m, piperidine-CH × 2 adjacent to alkyl
chain), 2.28 (2 H, m, piperidine C × 2 adjacent to CH-NH-Q2), 1.99 (2 , m, Q1-NHCH2CH2CH2),
1.75 (water signal overlaps m, ~2 H, piperidine CH × 2 adjacent to CH-NH-Q2).
13C NMR δ (ppm)(CDCl3): 152.3 (Q1-C2), 152.0 (Q2-C2), 150.4, 149.4, 149.3, 148.4, 135.1, 134.7, 129.1
(Q-C5), 129.0 (Q-C5), 125.6 (Q1-C6), 124.8 (Q2-C6), 121.7 (Q2-C8), 120.7 (Q1-C8), 117.5, 117.2, 99.6
(Q1-C3), 98.8 (Q2-C3), 58.2 (Q1-NHCH2CH2CH2), 52.5 (piperidine-C adjacent to alkyl chain), 49.5
(piperidine-CH-NH-Q2), 43.9 (Q1-NHCH2CH2CH2), 32.0 (piperidine-C adjacent to CH-NH-Q2), 24.4
(Q1-NHCH2CH2CH2).
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Note: Q1 and Q2 denote the quinoline ring system on the left and that on the right of the structure,
respectively, as shown above. Spectra are provided in Supplementary Materials (Example spectra:
Compound 6).
MS (ESI): m/z 480.17456 M + H (calculated 480.17163).
HPLC (method A) tR = 6.93 min (97% pure).
4.3. In Vitro Studies on Inhibition of P. falciparum Parasite Growth
The antiplasmodial activities of the compounds in this study were determined by methods described
previously [46,83]. The following three strains of P. falciparum were used: (1) a chloroquine- sensitive
strain, D6; (2) a chloroquine-resistant strain, Dd2, originally isolated from southeast Asia; and (3) a
second chloroquine-resistant strain, 7G8, originally isolated from Brazil. The parasites were maintained
continuously in culture, and asynchronous cultures were used for testing. Samples of the cultures
were diluted to 0.2% parasitemia and 0.2% hemocrit using uninfected red blood cells and complete
cell growth medium (RPMI-1640 with 0.5% Albumax II). Chloroquine was used as a positive control.
Solutions of chloroquine and the test compounds were made at 10 mM in DMSO. These solutions were
diluted into complete cell growth medium. In a 96-well microplate, the stock solutions were diluted
with complete cell growth medium to provide triplicate wells at concentrations between 0 and 10−4
M, each having a final volume of 100 µL. A given assay was performed using concentrations either
in the range of 0.025 to 250 nM or 2.5 to 2500 nM. The plates were then incubated under standard
culture conditions for 72 h before harvesting. The SYBR Green-I fluorescence-based method [83] was
used to read the plates using a 96-well plate fluorescence reader (Gemini-EM, Molecular Devices) with
excitation and emission wavelengths of 497 and 520 nm, respectively. Fluorescence was plotted against
the logarithm of drug concentration. IC50 values were then obtained by curve fitting by nonlinear
regression analysis using Prism (Graph Pad) software. The IC50 obtained for the chloroquine-positive
control was then used to “normalize” the IC50 values obtained for the test compounds to the chloroquine
IC50 values of 6.9 nMD6, 102 nMDd2, and 108 nM7G8 [46].
5. Conclusions
The high in vitro antiplasmodial activity of compound 6 and its synthetic accessibility makes this
a compound of interest for further development as a potential antimalarial drug, particularly if it were
found to be active against piperaquine-resistant strains of Plasmodium, which is the case (D. Fidock,
private communication). However, for bisquinolines as well as for other classes of compounds, high
in vitro activity does not necessarily predict high activity in vivo. Additionally, the substantially
elevated cytotoxicity of 6 relative to CQ are cause for possible concern. It may be possible to improve
this feature by the design of further analogs within this series.
Supplementary Materials: The following are available online, Synthetic details for all compounds not described
in the main manuscript; Figure C1–C12: Detailed 1H & 13C NMR spectra for Compound 6.
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